Nanoform Outlicenses Nanoencorafenib and Signs Development and Commercialisation Agreement with A.forall and IMGA
Nanoform Finland Plc | Press Release | October 14, 2025…
Nanoform Expands Commercial Presence in Asia with A&LS Pharma in South Korea
Nanoform Finland Plc | Press Release | September 30, 2025…
Nanoform Q3 2025 report day set for November 12th, 2025
Nanoform Finland Plc | Press Release | September 26, 2025…
Invitation to Nanoform’s Q2 2025 Report Presentation
Nanoform Finland Plc | Press Release | August 07, 2025…
Nanoform Secures €5 Million R&D Loan from Business Finland to Advance Clinical Development of Nanoapalutamide
Nanoform Finland Plc | Press Release | June 19, 2025…
Nanoform starts Pivotal Human Bioequivalence Studies of Nanoenzalutamide
Nanoform Finland Plc | Press Release | June 12, 2025…
Development of Nanoformed Trastuzumab for Subcutaneous Injection to Be Presented at DDF Summit in Berlin
Nanoform Finland Plc | Press Release | June 03, 2025…
Positive nanoform biologics respiratory data to be presented at drug delivery and formulation summit
Nanoform Finland Plc | Press Release | May 28, 2025…
Invitation to Nanoform’s Q1 2025 Report Presentation
Nanoform Finland Plc | Press Release | May 06, 2025…
Invitation to Nanoform’s Q4 and FY 2024 Report Presentation
Press release Nanoform Finland Plc February 13, 2025 11:00 a.m.…